Net Income

The pet and garden giant expands its animal health portfolio, acquiring a leader in eco-friendly cattle fly control to strengthen its position in a growing market.

Digital ad company Viewbix is acquiring Quantum X Labs, a deep-tech firm with a key patent in quantum error correction. Is this a visionary leap or a risky gamble?

The Nasdaq-listed restaurant operator confirms its board and auditor, signaling stability as it navigates a volatile stock performance and dynamic F&B sector.

In a key move, SAIC brings back Ravi Dankanikote from rival Peraton to lead growth amid a major corporate restructuring and competitive market.

As brands like She Said Yes champion lab-grown gems, consumers are embracing a new era of ethical, affordable luxury. What does this mean for tradition?

Riding a wave of record sales from its iDose TR implant, Glaukos is set to update investors on its explosive growth and the launch of its new drug, Epioxa.

AI data firm Hyperscale Data ties its fate to Bitcoin, with a treasury nearing its market value. A bold strategy or a risky gambit amid a major pivot?

After bombshell allegations and a stock plunge, Rezolve AI faces a major lawsuit investigation, raising critical questions about AI hype and corporate honesty.

Affluent buyers in Southeast Asia are trading property for lifestyle, fueling a 230% boom in branded residences. Why is experience the new ultimate luxury?

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Boise Cascade's acquisition of Holden Humphrey aims to reshape the Northeast building materials market, consolidating its power and expanding its product lines.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

A new report forecasts modest 2.6% growth for US construction in 2026, driven by data centers, water, and aviation, but challenged by major hurdles.